HR212, a recombinant protein composed of the heptad repeat, is a rationally designed human immunodeficiency virus type 1 (HIV-1) fusion inhibitor. This protein can be easily produced by Escherichia coli at a low cost. Previously, studies indicated that HR212 can efficiently inhibit the entry and replication of both laboratory and clinical HIV-1 strains, and this protein is more stable and less sensitive to proteinases than T20. The procedure of HIV-1 entry into the host cells can be divided into three main steps: gp120–CD4 interactions, coreceptor binding, and gp41 six-helix bundle formation and subsequent membrane fusion. The present study demonstrates that HR212 does not block gp120–CD4 binding or interfere with binding to the coreceptors CXCR4 and CCR5. Instead, HR212 efficiently blocks the six-helix bundle formation between peptides derived from the N-terminal heptad repeat (NHR) and the C-terminal heptad repeat (CHR) region of gp41. Fluorescence native polyacrylamide gel electrophoresis (FN-PAGE) indicated that HR212 could form a complex with peptide N36 to block gp41 fusogenic core formation. These results suggest that HR212 inhibits HIV-1 entry by targeting the NHR region of gp41. Therefore, HR212 can potentially be developed as a novel, high-efficiency, specific HIV-1 entry inhibitor.
Get full access to this article
View all access options for this article.
References
1.
PanC, LiuS, JiangS. HIV-1 gp41 fusion intermediate: A target for HIV therapeutics. J Formos Med Assoc, 2010; 109,2:94–105.
HeY, XiaoY, SongHet al.Design and evaluation of sifuvirtide, a novel HIV-1 fusion inhibitor. J Biol Chem, 2008; 283,17:11126–11134.
4.
MooreJP, DomsRW. The entry of entry inhibitors: A fusion of science and medicine. Proc Natl Acad Sci USA, 2003; 100,19:10598–10602.
5.
WyattR, SodroskiJ. The HIV-1 envelope glycoproteins: Fusogens, antigens, and immunogens. Science, 1998; 280,5371:1884–1888.
6.
ChanDC, KimPS. HIV entry and its inhibition. Cell, 1998; 93,5:681–684.
7.
MelikyanGB, MarkosyanRM, HemmatiHet al.Evidence that the transition of HIV-1 gp41 into a six-helix bundle, not the bundle configuration, induces membrane fusion. J Cell Biol, 2000; 151,2:413–423.
8.
LiuS, WuS, JiangS. HIV entry inhibitors targeting gp41: From polypeptides to small-molecule compounds. Curr Pharm Des, 2007; 13,2:143–162.
9.
HeY, ChengJ, LuHet al.Potent HIV fusion inhibitors against enfuvirtide-resistant HIV-1 strains. Proc Natl Acad Sci USA, 2008; 105,42:16332–16337.
10.
TashimaKT, CarpenterCC. Fusion inhibition—a major but costly step forward in the treatment of HIV-1. N Engl J Med, 2003; 348,22:2249–2250.
11.
NiL, GaoGF, TienP. Rational design of highly potent HIV-1 fusion inhibitory proteins: Implication for developing antiviral therapeutics. Biochem Biophys Res Commun, 2005; 332,3:831–836.
12.
PangW, WangRR, YangLMet al.Recombinant protein of heptad-repeat HR212, a stable fusion inhibitor with potent anti-HIV action in vitro. Virology, 2008; 377,1:80–87.
13.
LouisJM, BewleyCA, CloreGM. Design and properties of N(CCG)-gp41, a chimeric gp41 molecule with nanomolar HIV fusion inhibitory activity. J Biol Chem, 2001; 276,31:29485–29489.
14.
DengY, ZhengQ, KetasTJet al.Protein design of a bacterially expressed HIV-1 gp41 fusion inhibitor. Biochemistry, 2007; 46,14:4360–4369.
15.
LiuJJ, ReidG, JiangYet al.Activity of HIV entry and fusion inhibitors expressed by the human vaginal colonizing probiotic Lactobacillus reuteri RC-14. Cell Microbiol, 2007; 9,1:120–130.
16.
HuangJH, YangHW, LiuSet al.The mechanism by which molecules containing the HIV gp41 core-binding motif HXXNPF inhibit HIV-1 envelope glycoprotein-mediated syncytium formation. Biochem J, 2007; 403,3:565–571.
17.
JiangS, LuH, LiuSet al.N-substituted pyrrole derivatives as novel human immunodeficiency virus type 1 entry inhibitors that interfere with the gp41 six-helix bundle formation and block virus fusion. Antimicrob Agents Chemother, 2004; 48,11:4349–4359.
18.
WangH, QiZ, GuoAet al.ADS-J1 inhibits human immunodeficiency virus type 1 entry by interacting with the gp41 pocket region and blocking fusion-active gp41 core formation. Antimicrob Agents Chemother, 2009; 53,12:4987–4998.
19.
LiuS, LuH, NiuJet al.Different from the HIV fusion inhibitor C34, the anti-HIV drug Fuzeon (T-20) inhibits HIV-1 entry by targeting multiple sites in gp41 and gp120. J Biol Chem, 2005; 280,12:11259–11273.
20.
ZhaoQ, ErnstJT, HamiltonADet al.XTT formazan widely used to detect cell viability inhibits HIV type 1 infection in vitro by targeting gp41. AIDS Res Hum Retroviruses, 2002; 18,14:989–997.
21.
ZhaoQ, HeY, AlespeitiG, DebnathAK. A novel assay to identify entry inhibitors that block binding of HIV-1 gp120 to CCR5. Virology, 2004; 326,2:299–309.
22.
DorrP, WestbyM, DobbsSet al.Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother, 2005; 49,11:4721–4732.
23.
LiuS, ZhaoQ, JiangS. Determination of the HIV-1 gp41 fusogenic core conformation modeled by synthetic peptides: Applicable for identification of HIV-1 fusion inhibitors. Peptides, 2003; 24,9:1303–1313.
24.
JiangS, LinK, ZhangL, DebnathAK. A screening assay for antiviral compounds targeted to the HIV-1 gp41 core structure using a conformation-specific monoclonal antibody. J Virol Methods, 1999; 80,1:85–96.
25.
LuM, BlacklowSC, KimPS. A trimeric structural domain of the HIV-1 transmembrane glycoprotein. Nat Struct Biol, 1995; 2,12:1075–1082.
26.
ScholsD, EsteJA, HensonG, De ClercqE. Bicyclams, a class of potent anti-HIV agents, are targeted at the HIV coreceptor fusin/CXCR-4. Antiviral Res, 1997; 35,3:147–156.
27.
JiangS, LinK, LuM. A conformation-specific monoclonal antibody reacting with fusion-active gp41 from the human immunodeficiency virus type 1 envelope glycoprotein. J Virol, 1998; 72,12:10213–10217.
28.
OldfieldV, KeatingGM, PloskerG. Enfuvirtide: A review of its use in the management of HIV infection. Drugs, 2005; 65,8:1139–1160.
29.
PeuchantO, CapdepontS, RagnaudJMet al.Primary resistance to enfuvirtide (T20) in recently HIV-1 infected, antiretroviral-naive patients from the ANRS Aquitaine Cohort. Antivir Ther, 2007; 12,4:559–562.
30.
LiuS, JingW, CheungBet al.HIV gp41 C-terminal heptad repeat contains multifunctional domains. Relation to mechanisms of action of anti-HIV peptides. J Biol Chem, 2007; 282,13:9612–9620.
31.
NaitoT, IzumiK, KodamaEet al.SC29EK, a peptide fusion inhibitor with enhanced alpha-helicity, inhibits replication of human immunodeficiency virus type 1 mutants resistant to enfuvirtide. Antimicrob Agents Chemother, 2009; 53,3:1013–1018.
32.
DwyerJJ, WilsonKL, DavisonDKet al.Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus. Proc Natl Acad Sci USA, 2007; 104,31:12772–12777.
33.
MiyauchiK, KimY, LatinovicOet al.HIV enters cells via endocytosis and dynamin-dependent fusion with endosomes. Cell, 2009; 137,3:433–444.
34.
VeazeyRS, KlassePJ, SchaderSMet al.Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion. Nature, 2005; 438,7064:99–102.
